Nattokinase

Mechanism of action

Proposed mechanisms: (1) Direct fibrinolysis: proteolytic activity on fibrin. (2) Modulation of endogenous fibrinolysis: in some studies, an increase in markers of fibrinolytic activity (e.g., tPA) and/or a reduction in inhibitors (e.g., PAI-1), with results that are not always consistent. (3) Hemorheological effects: possible reduction in viscosity and improvement in microcirculatory flow in some models/endpoints. (4) Effects on blood pressure: hypotheses include improved endothelial function and possible influence on vasoactive peptides; clinical data suggest modest reductions in blood pressure in some individuals. (5) Anti-inflammatory/anti-atherogenic effects: preclinical evidence indicates potential effects on oxidative stress and vascular inflammation, but clinical translation remains uncertain.

Supported benefits

• Modest reduction in blood pressure (especially systolic) in some studies of adults with elevated or borderline blood pressure (moderate)
• Increase in markers of fibrinolytic activity and potential reduction in some coagulation/fibrin markers in acute and short-term studies (moderate)
• Possible improvement in circulation/microcirculation parameters and blood viscosity (variable and non-standardized endpoints) (limited)
• Indirect support for cardiometabolic health through improvement in vascular/endothelial function (plausible hypothesis, inconclusive clinical evidence) (emerging)

Safety & side effects

• Gastrointestinal disturbances (nausea, abdominal discomfort) in a minority of individuals.
• Headache or dizziness (non-specific; sometimes associated with blood pressure changes).
• Increased risk of bleeding/bruising, especially in predisposed individuals or those taking concomitant medications (the most clinically relevant event).
• Allergic reactions: possible, especially in individuals sensitive to soy or product components (depends on purity/formulation).

FAQ

Does nattokinase “thin the blood”?

In scientific terms, it is more accurate to speak of fibrinolytic activity (the breakdown of fibrin) and possible modulation of the fibrinolytic system. This may translate into an overall pro-bleeding effect in some contexts, especially if combined with other agents that reduce clotting.

Is it useful for metabolic health (blood sugar, insulin, body fat)?

It is not a supplement primarily studied for blood sugar control or weight loss. Any usefulness in “metabolic health” is indirect, through vascular parameters (blood pressure, endothelium, microcirculation) that are often altered in metabolic syndrome.

Can it improve athletic performance?

There is no solid evidence of a direct improvement in performance (strength, power, VO2max). If a benefit exists, it is more plausibly indirect and related to circulation/blood pressure in specific subject profiles.

Is it better to have mg or FU on the label?

FU (Fibrinolytic Units) describe enzymatic activity and make products more comparable. Mg may be of limited informational value if not accompanied by activity standardization.

Is it equivalent to eating natto?

Natto is a complex food matrix (proteins, fiber, vitamin K2, fermentative compounds). Nattokinase is a single isolated/standardized enzyme: it is not automatically equivalent to the overall effects of the food.

Are there signs indicating that it may not be suitable for me?

A tendency to bruise easily, frequent bleeding, anticoagulant/antiplatelet therapy, planned procedures, or sports with a high risk of trauma are contexts in which risk assessment is particularly important.